References

  1. Capoluongo, E. et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology 44, 187–197 (2017).
  2. Ledermann, J. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24 Suppl 6, vi24-32 (2013).
  3. NHS England » National Cancer Drugs Fund list. https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/.
  4. Lynparza 100 mg and 150 mg Film-Coated Tablets SmPC.
  5. Alsop, K. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30, 2654–2663 (2012).
  6. Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581–2586 (2008).
  7. Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology 15, 852–861 (2014).
  8. Gourley, C. et al. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J. Clin. Oncol. 28, 2505–2511 (2010).
  9. Tan, D. S. P. & Kaye, S. B. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? Am Soc Clin Oncol Educ Book 114–121 (2015) doi:10.14694/EdBook_AM.2015.35.114.
  10. Bolton, K. L. et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307, 382–390 (2012).
  11. Petrucelli, N., Daly, M. B. & Feldman, G. L. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet. Med. 12, 245–259 (2010).
  12. Surbone, A. Social and ethical implications of BRCA testing. Ann. Oncol. 22 Suppl 1, i60-66 (2011).
  13. Finch, A. et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296, 185–192 (2006).
  14. Domchek, S. M. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304, 967–975 (2010).
  15. Ledermann, J. A., Sessa, C. & Colombo, N. appendix 7: Ovarian cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Gynaecological-Malignancies). Ann Oncol 27, v145–v145 (2016).
  16. Pal, T. et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104, 2807–2816 (2005).
  17. Pennington, K. P. et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764–775 (2014).
  18. Moschetta, M., George, A., Kaye, S. B. & Banerjee, S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann. Oncol. 27, 1449–1455 (2016).
  19. Vergote, I. et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur. J. Cancer 69, 127–134 (2016).
  20. Ngeow, J. & Eng, C. Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet. npj Genomic Medicine 1, 15006 (2016).
  21. Vergote, I., Bours, V., Blaumeiser, B. & Baurain, J.-F. New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes. Facts Views Vis Obgyn 8, 161–171 (2016).
  22. Plon, S. E. et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29, 1282–1291 (2008).
  23. Cree, I. A. et al. Guidance for laboratories performing molecular pathology for cancer patients. Journal of Clinical Pathology 67, 923–931 (2014).
  24. Wallace, A. J. New challenges for BRCA testing: a view from the diagnostic laboratory. Eur J Hum Genet 24, S10–S18 (2016).
  25. Corr, B. R., Behbakht, K. & Spillman, M. A. Gynecologic Biopsy for Molecular Profiling: A Review for the Interventional Radiologist. Semin Intervent Radiol 30, 417–424 (2013).
  26. Goranova, T. et al. Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium. Br. J. Cancer 116, 1294–1301 (2017).
  27. Chaturvedi, D. A., Rogan, J. & Wallace, D. A. Generic guidelines: Pan-pathology specimen handling towards optimal morphological and genomic analysis (prepared for the Manchester cancer pathway). 7.
  28. tBRCA test request form Royal Marsden July 2019.pdf.
  29. tBRCA test request form Manchester July 2019.pdf.

GB-16387 - Date of preparation: December 2019